MYSTICOL: A multisite, double-blind, randomized, placebo-controlled trial of rimabotulinumtoxinB for the treatment of sialorrhea in Parkinsons disease (PD) and other neurological conditions (P3.026)

Conclusions:Injection of rimabotulinumtoxinB (Myobloc) into the parotid and submandibular glands wase effective for the treatment of sialorrhea in patients with PD and other neurologic disorders, atf both 2500U and 3500U treatment arms. Injections were generally well toleratedStudy Supported by: US WorldMedsDisclosure: Dr. Isaacson has nothing to disclose. Dr. Jackson has received personal compensation for activities with GLG, Guidepoint Global, Marathon Pharmaceuticals, OneWorld Meds and Cytokinetics as a consultant. Dr. Jackson has received research support from OneWorld Meds and Cytokinetics. Dr. Molho has received personal compensation for activities with Lundbeck Research USA, Inc. and US WorldMeds as a consult and/or speaker. Dr. Trosch has received personal compensation for activities with Ipsen as a speaker and consultant. Dr. Ondo has received personal compensation for activities with TEVA, UCB Pharma, Lundbeck Research USA, Inc, ACADIA, and IMPAX as speaker and consultant. Dr. Clinch has received personal compensation for activities with US WorldMeds as an employee.
Source: Neurology - Category: Neurology Authors: Tags: Movement Disorders: Dystonia and Neurotoxin Therapies Source Type: research